kriyatherapeutics.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $2.22B
Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/23/2023 | Series C-1 | $60.14MM | $xx.xx | $914.46MM | Bluebird Ventures, Cam Capital, Dexcel Pharma, Foresite Capital, Jdrf T1d Fund, Lightswitch Capital, Narya Capital, Patient Square Capital, Qvt, Transhuman Capital | |
Price per Share
$xx.xx
Shares Outstanding
8,312,005
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bluebird Ventures, Cam Capital, Dexcel Pharma, Foresite Capital, Jdrf T1d Fund, Lightswitch Capital, Narya Capital, Patient Square Capital, Qvt, Transhuman Capital
|
||||||
05/16/2022 | Series C | $369.86MM | $xx.xx | $768.28MM | Bluebird Ventures, Cam Capital, Dexcel Pharma, Foresite Capital, Jdrf T1d Fund, Lightswitch Capital, Narya Capital, Patient Square Capital, Qvt, Transhuman Capital | |
Price per Share
$xx.xx
Shares Outstanding
51,119,663
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bluebird Ventures, Cam Capital, Dexcel Pharma, Foresite Capital, Jdrf T1d Fund, Lightswitch Capital, Narya Capital, Patient Square Capital, Qvt, Transhuman Capital
|
||||||
07/14/2021 | Series B | $100MM | $xx.xx | $319.24MM | Alumni Ventures, Amplo, Bluebird Ventures, Cam Capital, Dexcel Pharma, Foresite Capital, Hongkou, Jdrf T1d Fund, Narya Capital, Patient Square Capital, Qvt, Transhuman Capital, Woodline Partners Lp | |
Price per Share
$xx.xx
Shares Outstanding
16,585,673
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Amplo, Bluebird Ventures, Cam Capital, Dexcel Pharma, Foresite Capital, Hongkou, Jdrf T1d Fund, Narya Capital, Patient Square Capital, Qvt, Transhuman Capital, Woodline Partners Lp
|
||||||
05/12/2020 | Series A-2 | $5.13MM | $xx.xx | $197.6MM | Amplo, Asia Alpha, Bluebird Ventures, Dexcel Pharma, Foresite Capital, Narya Capital, Paul Manning, Qvt, Transhuman Capital | |
Price per Share
$xx.xx
Shares Outstanding
1,291,381
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amplo, Asia Alpha, Bluebird Ventures, Dexcel Pharma, Foresite Capital, Narya Capital, Paul Manning, Qvt, Transhuman Capital
|
||||||
05/12/2020 | Series A-1 | $82.5MM | $xx.xx | $197.6MM | Amplo, Asia Alpha, Bluebird Ventures, Dexcel Pharma, Foresite Capital, Narya Capital, Paul Manning, Qvt, Transhuman Capital | |
Price per Share
$xx.xx
Shares Outstanding
16,598,254
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amplo, Asia Alpha, Bluebird Ventures, Dexcel Pharma, Foresite Capital, Narya Capital, Paul Manning, Qvt, Transhuman Capital
|